SCHEMBL11919912

SCHEMBL11919912

COc1ccc(-n2c(SC)nnc2-c2ccncc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 8/20 0.58
TNKS O95271 4/20 0.58
MAPT P10636 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
THRB P10828 1/20 0.58
CYP3A4 P08684 2/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
SULT2A1 Q06520 1/20 0.55
NR5A1 Q13285 1/20 0.55
AXIN2 Q9Y2T1 1/20 0.55
TP53 P04637 3/20 0.53
TSHR P16473 3/20 0.53
ALDH1A1 P00352 2/20 0.53
TLR8 Q9NR97 1/20 0.51
MAPK1 P28482 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
OXTR P30559 1/20 0.50
USP2 O75604 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20869674 0.85 HSD17B10 (0.56) TNKS2TNKSMAPTSMN1; SMN2CYP3A4
SCHEMBL20869595 0.85 TSHR (0.71) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL6251016 0.84 ALDH1A1 (0.67) TNKS2MAPTSMN1; SMN2TP53TSHR
SCHEMBL13048293 0.83 ALDH1A1 (0.55) MAPTCYP3A4CYP2D6CYP2C9TP53
SCHEMBL6403463 0.80 CYP3A4 (0.73) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919914 0.80 OXTR (0.52) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11920079 0.80 OXTR (0.52) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL11919913 0.80 OXTR (0.52) TNKS2TNKSMAPTSMN1; SMN2THRB
SCHEMBL6192012 0.79 ALPG (0.69) TNKS2TNKSMAPTSMN1; SMN2THRB
Hydrochloric Acid SCHEMBL11375354 0.78 TLR8 (0.57) TNKS2TNKSMAPTTHRBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TNKS2 1460/4885TNKS 1665/4885MAPT 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.